investorsHD

inHD

Link copied

Novavax signs licensing agreement with Pfizer for vaccine development.

companies :: 1day ago :: source - reuters

By Reuters

(Reuters) - Novavax said on Tuesday it has entered into a licensing agreement with Pfizer (PFE.N) to develop vaccine products for infectious diseases.

Pfizer will gain access to Novavax's Matrix-MT adjuvant technology and have control over all matters relating to the development, manufacture and commercialization of any products that contain the adjuvant, apart from its delivery and supply.

Novavax said it will receive an upfront payment of $30 million in the first quarter of 2026, and be eligible to receive up to an additional $500 million in milestone payments.

Shares of Novavax climbed 2% in premarket trading.

Reporting by Christy Santhosh in Bengaluru; Editing by Shinjini Ganguli


This week on Reuters

This week top market trends.

Recent global market news

investorsHD Media

Subscribe to our handles,follow the news 24/7

investorsHD & partners uses cookie to ensure your best user experience,by continue using investorsHD,we assume that you have agreed with our cookie terms & policy , to have more privacy experience,simply switch your browser to privacy mode, Learn about cookie

×